Targeting the Tumor Microenvironment to Enhance Pediatric Brain Cancer Treatment

Cancer Journal (United States)

Volumn 21, Issue 4, 2015, Pages 307-313

  Batista, Ana ^a   Riedemann, Lars ^a   Vardam, Trupti ^a   Jain, Rakesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Brain cancers; pediatric brain tumors; pediatric oncology; targeted stromal therapies; tumor microenvironment

Indexed keywords

BEVACIZUMAB; PEMBROLIZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; NERVE CELL ADHESION MOLECULE; NERVE PROTEIN; NEUROLIGIN 3; PIGF PROTEIN, HUMAN;

BLOOD BRAIN BARRIER; BRAIN CANCER; CANCER CELL; CELL INVASION; CELL SURVIVAL; CHEMORADIOTHERAPY; CHILDHOOD CANCER; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW; STROMA CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; BRAIN NEOPLASMS; CHILD; GLIOMA; IMMUNOLOGY; MEDULLOBLASTOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL ADHESION MOLECULES, NEURONAL; CHILD; GLIOMA; HUMANS; IMMUNOMODULATION; MEDULLOBLASTOMA; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; PARACRINE COMMUNICATION; TUMOR MICROENVIRONMENT;

EID: 84938603789     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000125     Document Type: Review

References (90)

1. Johnson KJ, Cullen J, Barnholtz-Sloan JS, et al. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomarkers Prev. 2014;23:2716-2736.
2. Pollack IF, Jakacki RI. Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol. 2011;7:495-506.
3. Vinchon M, Baroncini M, Leblond P, et al. Morbidity and tumor-related mortality among adult survivors of pediatric brain tumors: a review. Childs Nerv Syst. 2011;27:697-704.
4. Dubuc AM, Northcott PA, Mack S, et al. The genetics of pediatric brain tumors. Curr Neurol Neurosci Rep. 2010;10:215-223.
5. Olson JM. Therapeutic opportunities for medulloblastoma come of age. Cancer Cell. 2014;25:267-269.
6. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28:3061-3068.
7. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123: 465-472.
8. Witt H, Korshunov A, Pfister SM, et al. Molecular approaches to ependymoma: the next step(s). Curr Opin Neurol. 2012;25:745-750.
9. Zhang J,WuG,Miller CP, et al.Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45:602-612.
10. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205-2218.
11. Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 2013;73: 4965-4977.
12. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423-1437.
13. Charles NA, Holland EC, Gilbertson R, et al. The brain tumor microenvironment. Glia. 2012;60:502-514.
14. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610-622.
15. Emmenegger BA, Hwang EI, Moore C, et al. Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma. Oncogene. 2013;32:4181-4188.
16. Roussel MF, Hatten ME. Cerebellum development and medulloblastoma. Curr Top Dev Biol. 2011;94:235-282.
17. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A. 2003;100:13513-13518.
18. Yang L, Jackson E,Woerner BM, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007; 67:651-658.
19. Anderton JA, Lindsey JC, Lusher ME, et al. Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol. 2008;10:981-994.
20. LiangY, DiehnM,BollenAW, et al. Type I collagen is overexpressed inmedulloblastoma as a component of tumor microenvironment. J Neurooncol. 2008;86:133-141.
21. MacDonald TJ, Vezina G, Stewart CF, et al. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2013;15: 1438-1444.
22. Wöhrle S,Weiss A, ItoM, et al. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One. 2013;8:e77652.
23. Snuderl M, Batista A, Kirkpatrick ND, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 2013;152:1065-1076.
24. Lassen U, Nielsen DL, Sørensen M, et al. A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Br J Cancer. 2012;106:678-684.
25. Martinsson-Niskanen T, Riisbro R, Larsson L, et al. Monoclonal antibody TB-403: a first-in-human, phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin Ther. 2011;33:1142-1149.
26. Venkatesh HS, Johung TB, Caretti V, et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell. 2015;161:803-816.
27. Gore L,DeGregori J, Porter CC. Targeting developmental pathways in children with cancer: what price success? Lancet Oncol. 2013;14:e70-e78.
28. Kool M, Jones DT, Jäger N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25:393-405.
29. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131-1138.
30. Fangusaro J, Gururangan S, Poussaint TY, et al. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 2013;119:4180-4187.
31. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28:3069-3075.
32. Gururangan S, Fangusaro J, Young Poussaint T, et al. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma-a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2012;14:1404-1412.
33. Sie M, den Dunnen WF, Hoving EW, et al. Anti-angiogenic therapy in pediatric brain tumors: an effective strategy? Crit Rev Oncol Hematol. 2014; 89:418-432.
34. Lu-Emerson, Duda DG, Emblem KE, et al. Lesson from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015;33:1197-1213.
35. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605-622.
36. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298-307.
37. Chae SS, KamounWS, Farrar CT, et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res. 2010;16:3618-3627.
38. Brown JL, Cao ZA, Pinzon-Ortiz M, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther. 2010;9:145-156.
39. Daly C, Eichten A, Castanaro C, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013;73:108-118.
40. Kienast Y, Klein C, Scheuer W, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res. 2013;19:6730-6740.
41. Rigamonti N, Kadioglu E, Keklikoglou I, et al. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 2014;8:696-706.
42. Srivastava K, Hu J, Korn C, et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell. 2014;26:880-895.
43. Kelley RK, van Loon K, TolcherAW, et al. Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): results from hepatocellular carcinoma (HCC) cohort. J Clin Oncol. 2014;32:5 s(suppl; abstr 2540).
44. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071-1121.
45. Huang Y, Stylianopoulos T, Duda DG, et al. Benefits of vascular normalization are dose and time dependent [letter]. Cancer Res. 2013;73:7144-7146.
46. Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109:17561-17566.
47. Levin VA, Mendelssohn ND, Chan J, et al. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. J Neurooncol. 2015;122:145-150.
48. Lorgis V,Maura G, Coppa G, et al. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol. 2012;107:351-358.
49. Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010;12:49-57.
50. Piao Y, Liang J, Holmes L, et al. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013;19:4392-4403.
51. Batchelor TT, Gerstner ER, Emblem KE, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013; 110:19059-19064.
52. Sorensen AG, Emblem KE, Polaskova P, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012;72:402-407.
53. Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58-69.
54. Ousman SS, Kubes P. Immune surveillance in the central nervous system. Nat Neurosci. 2012;15:1096-1101.
55. Kivisäkk P, Mahad DJ, Callahan MK, et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A. 2003; 100:8389-8394.
56. Kmiecik J, Poli A, Brons NH, et al. Elevated CD3+ and CD8+ tumorinfiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013;264: 71-83.
57. Kmiecik J, Zimmer J, Chekenya M. Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J Neurooncol. 2014;116:1-9.
58. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010;120:1368-1379.
59. Abad C, Nobuta H, Li J, et al. Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J Leukoc Biol. 2014;95:357-367.
60. Atai NA, Bansal M, Lo C, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology. 2011;132:39-48.
61. Flies DB, Han X, Higuchi T, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity. J Clin Invest. 2014;124: 1966-1975.
62. Sarkar S, Döring A, Zemp FJ, et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci. 2014; 17:46-55.
63. Sayour EJ, McLendon P, McLendon R, et al. Increased proportion of FoxP3 + regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother. 2015;64:419-427.
64. Griesinger AM, Birks DK, Donson AM, et al. Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol. 2013; 191:4880-4888.
65. GriesingerAM, DonsonAM, Foreman NK. Immunotherapeutic implications of the immunophenotype of pediatric brain tumors. Oncoimmunology. 2014; 3:e27256.
66. Gate D, Danielpour M, Rodriguez J Jr, et al. T-cell TGF- signaling abrogation restricts medulloblastoma progression. Proc Natl Acad Sci U S A. 2014;111:E3458-E3466.
67. Ardon H, de Vleeschouwer S, van Calenbergh F, et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer. 2010;54:519-525.
68. Congdon KL, Gedeon PC, SuryadevaraCM, et al. Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol. 2014;16 (suppl 8):viii20-viii25.
69. Donson AM, Birks DK, Barton VN, et al. Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J Immunol. 2009;183:7428-7440.
70. Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J ClinOncol. 2014;32:2050-2058.
71. Pollack IF, Jakacki RI, Butterfield LH, et al. Peptide vaccine therapy for childhood gliomas. Neurosurgery. 2013;60(suppl 1):113-119.
72. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-1517.
73. Wainwright DA, Chang AL, DeyM, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20:5290-5301.
74. Belcaid Z, Phallen JA, Zeng J, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One. 2014;9:e101764.
75. Newcomb EW, Lukyanov Y, Kawashima N, et al. Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse glioma model. Radiat Res. 2010;173:426-432.
76. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11:702-711.
77. Bouzin C, Brouet A, de Vriese J, et al. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol. 2007;178:1505-1511.
78. Griffioen AW, Damen CA, Blijham GH, et al. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood. 1996;88:667-673.
79. Griffioen AW, Damen CA, Martinotti S, et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 1996;56:1111-1117.
80. Melder RJ, Koenig GC,Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996;2: 992-997.
81. Buckanovich RJ, Facciabene A, Kim S, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008;14:28-36.
82. Nummer D, Suri-Payer E, Schmitz-Winnenthal H, et al. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst. 2007;99:1188-1199.
83. Della Porta M, Danova M, Rigolin GM, et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology. 2005;68:276-284.
84. Gabrilovich DI, ChenHL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-1103.
85. Takahashi A, Kono K, Ichihara F, et al. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother. 2004; 53:543-550.
86. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475: 226-230.
87. Shojaei F,Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007;450:825-831.
88. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6:409-421.
89. Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632-642.
90. Nishino M, Giobbie-Hurder A, Ramaiya NH, et al. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014;2:40.